Sutton L N, Packer R J, Schut L
University of Pennsylvania School of Medicine, Philadelphia.
Neurosurg Clin N Am. 1990 Jan;1(1):97-109.
It is obvious that the past decade has witnessed considerable progress in the management of children with medulloblastoma. Better surgical technique has led to more aggressive surgery with less morbidity. The use of staging has led to reduction in radiation therapy doses in some patients and will, it is hoped, lead to better neuropsychological outcome. The use of adjuvant chemotherapy in high-risk patients is delaying recurrence. It remains unknown, however, whether the patient with a medulloblastoma is ever "cured." Certainly, in the future, control of this tumor will depend on new therapeutic modalities, which will be developed on the basis of a better understanding of the biology of these primitive tumors. A better understanding of tumor immunology, cytogenetics, and biochemistry is a goal for the future.
显然,在过去十年中,髓母细胞瘤患儿的治疗取得了显著进展。更好的手术技术使得手术更加积极,且发病率更低。分期的应用使得部分患者的放射治疗剂量得以降低,并且有望带来更好的神经心理学结果。高危患者使用辅助化疗可延缓复发。然而,髓母细胞瘤患者是否能真正“治愈”仍是未知数。当然,未来对这种肿瘤的控制将依赖于新的治疗方式,这些方式将基于对这些原始肿瘤生物学的更深入理解而开发。更好地理解肿瘤免疫学、细胞遗传学和生物化学是未来的一个目标。